| Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ... Journal of Clinical Oncology 35 (7), 709, 2017 | 1054 | 2017 |
| High response rate to PD-1 blockade in desmoplastic melanomas Z Eroglu, JM Zaretsky, S Hu-Lieskovan, DW Kim, A Algazi, DB Johnson, ... Nature 553 (7688), 347-350, 2018 | 301 | 2018 |
| Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort SJE Hwang, G Carlos, D Wakade, K Byth, BY Kong, S Chou, MS Carlino, ... Journal of the American Academy of Dermatology 74 (3), 455-461. e1, 2016 | 293 | 2016 |
| Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial GV Long, V Atkinson, JS Cebon, MB Jameson, BM Fitzharris, CM McNeil, ... The Lancet Oncology 18 (9), 1202-1210, 2017 | 276 | 2017 |
| Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma RE Vilain, AM Menzies, JS Wilmott, H Kakavand, J Madore, A Guminski, ... Clinical Cancer Research 23 (17), 5024-5033, 2017 | 239 | 2017 |
| Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma E Liniker, AM Menzies, BY Kong, A Cooper, S Ramanujam, S Lo, ... OncoImmunology 5 (9), e1214788, 2016 | 154 | 2016 |
| Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy S Bowyer, P Prithviraj, P Lorigan, J Larkin, G McArthur, V Atkinson, ... British journal of cancer 114 (10), 1084-1089, 2016 | 133 | 2016 |
| Residual FDG‐PET metabolic activity in metastatic melanoma patients with prolonged response to anti‐PD‐1 therapy BY Kong, AM Menzies, CAB Saunders, E Liniker, S Ramanujam, ... Pigment Cell & Melanoma Research, 2016 | 95 | 2016 |
| Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma BY Kong, KP Micklethwaite, S Swaminathan, RF Kefford, MS Carlino Melanoma research 26 (2), 202-204, 2016 | 93 | 2016 |
| Dendritic cells as cancer therapeutics CE Bryant, S Sutherland, B Kong, MS Papadimitrious, PD Fromm, ... Seminars in cell & developmental biology 86, 77-88, 2019 | 54 | 2019 |
| Allosteric effect of ATP on Na+, K+-ATPase conformational kinetics RJ Clarke, HJ Apell, BY Kong Biochemistry 46 (23), 7034-7044, 2007 | 43 | 2007 |
| Biology and treatment of BRAF mutant metastatic melanoma BY Kong, MS Carlino, AM Menzies Melanoma Management 3 (1), 33-45, 2016 | 38 | 2016 |
| The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy? B Oh, F Boyle, N Pavlakis, S Clarke, T Eade, G Hruby, G Lamoury, ... Cancers 13 (19), 4824, 2021 | 35 | 2021 |
| Dependence of Na+-K+ pump current-voltage relationship on intracellular Na+, K+, and Cs+ in rabbit cardiac myocytes PS Hansen, KA Buhagiar, BY Kong, RJ Clarke, DF Gray, HH Rasmussen American Journal of Physiology-Cell Physiology 283 (5), C1511-C1521, 2002 | 32 | 2002 |
| Identification of potential regulatory sites of the Na+, K+-ATPase by kinetic analysis BY Kong, RJ Clarke Biochemistry 43 (8), 2241-2250, 2004 | 31 | 2004 |
| A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission JL Hsu, CE Bryant, MS Papadimitrious, B Kong, RE Gasiorowski, ... Oncoimmunology 7 (4), e1419114, 2018 | 30 | 2018 |
| On the other side: manipulating the immune checkpoint landscape of dendritic cells to enhance cancer immunotherapy BY Kong, H Bolton, JW Kim, PA Silveira, PD Fromm, GJ Clark Frontiers in oncology 9, 50, 2019 | 16 | 2019 |
| Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma. Z Eroglu, DW Kim, DB Johnson, AP Algazi, RR Munhoz, E Liniker, B Kong, ... ASCO Annual Meeting Proceedings 33 (15_suppl), 9011, 2015 | 14 | 2015 |
| Dietary cholesterol alters Na+/K+ selectivity at intracellular Na+/K+ pump sites in cardiac myocytes KA Buhagiar, PS Hansen, BY Kong, RJ Clarke, C Fernandes, ... American Journal of Physiology-Cell Physiology 286 (2), C398-C405, 2004 | 14 | 2004 |
| Dietary cholesterol alters Na+/K+ selectivity at intracellular Na+/K+ pump sites in cardiac myocytes KA Buhagiar, PS Hansen, BY Kong, RJ Clarke, C Fernandes, ... American Journal of Physiology-Cell Physiology 286 (2), C398-C405, 2004 | 14 | 2004 |
Carlino Matteo SMelanoma Institute Australia; Westmead HospitalVerified email at sydney.edu.au
